Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab

Abstract
Sir, We present, to the best of our knowledge, the first case of a patient with severe resistant systemic lupus erythematosus (SLE) including the development of human antichimeric antibodies (HACA) after rituximab, who responded both clinically and serologically to an investigational humanized anti-CD20 monoclonal antibody (hA20) provided on a compassionate use basis by Immunomedics, Inc. (Morris Plains, NJ, USA).

This publication has 0 references indexed in Scilit: